Skip to main content
Premium Trial:

Request an Annual Quote


2:30 PM
US Eastern

Sponsored by Hologic

The Importance of Flexibility in Respiratory Testing Platforms: Accommodating Diverse Patient Needs and Changing Viral Incidence Throughout the Year

Respiratory testing decisions can be impacted by patient type (immunocompromised, pediatric, pregnant, elderly), patient risk (inpatient, outpatient, travel history, geography), and time of year (incidence of different respiratory viruses throughout the year). These unique attributes necessitate flexible testing algorithms to best serve varied patient populations and changing respiratory testing needs throughout the year. Additionally, streamlined workflows for respiratory testing can potentially decrease costs, hands-on time, and FTEs needed to process all samples in the laboratory.

In this webinar:

  • Rangaraj Selvarangan, director of the microbiology laboratory at Children's Mercy Hospital, will present clinical trial data on a recently FDA-cleared molecular test for respiratory viruses that detects and differentiates SARS-CoV-2, influenza A, influenza B, and RSV.
  • Jim Dunn, director of the medical microbiology and virology laboratories at Texas Children's Hospital, will review the respiratory testing algorithm used at the hospital, discussing how test ordering is modified throughout the year to accommodate seasonality, how different platforms are utilized to best serve patients, and how flexible testing platforms allow for optimal management of diagnostic stewardship.
  • Matthew Binnicker, medical director of the clinical virology laboratory at Mayo Clinic, will discuss the respiratory testing algorithm employed by a large reference laboratory with a diverse patient population, including a result masking strategy to accommodate different test order combinations. He will also review the 2023-2024 winter respiratory season experienced at Mayo Clinic and provide his perspective on what respiratory viral activity we might see in the year ahead.

Sponsored by

11:30 AM
US Eastern

Sponsored by Guardant Health

Panel Talk: Unlocking Global Access to Liquid Biopsy Through In-Country Testing

Enabling global access to precision medicine with liquid biopsy CGP testing has been challenging. Obstacles include standardizing a complex liquid biopsy testing workflow globally and varying regional healthcare guidelines and regulatory policies.

In this panel discussion, Jean-Francois Martini, head of biomarker clinical assay and technology at Pfizer, and Lawrence Wang, chief financial officer at Adicon, will take a deep look into challenges, considerations, and breakthroughs in enabling access to the China population for global clinical trials. Vafa Amirkia, Guardant Health’s director of biopharma business development in China, will lead the discussion.

Following the discussion, Simranjit Singh, CEO of the Asia, Middle East, and Africa (AMEA) regions at Guardant, will highlight how the company has successfully enabled in-country access to their robust, validated liquid biopsy technology for patients around the world.

The discussion and presentation will be followed by an audience Q&A.

Sponsored by

11:00 AM
US Eastern

Sponsored by Pillar Biosciences

Accelerating Access to Liquid Biopsy Testing With Kitted NGS Solutions

To date, liquid biopsy testing has largely been provided by large centralized CLIA reference laboratories. To help maximize global access to liquid biopsy and associated targeted therapies, biopharmaceutical organizations are interested in establishing diagnostic partnerships to drive liquid biopsy testing at local and regional laboratories, leveraging in-house NGS platforms to provide testing closer to patients, enabling more timely, efficient, and cost-effective care.

In this webinar, John Longshore, head of scientific affairs for global oncology diagnostics at AstraZeneca, and Pantelis Constantoulakis, the scientific director at Genotypos Science Labs, will discuss:


  1. The importance of liquid biopsy testing in guiding access to precision therapies and clinical trials.
  2. The challenges faced by global pharmaceutical companies regarding patient access to liquid biopsy and new strategies to improve access.
  3. A laboratory evaluation of the performance, workflow, and cost of Pillar Biosciences’ suite of kitted liquid biopsy-based assays.

Sponsored by